Exploratory Insights into Gastric Cancer Metabolism Through Amino Acid and Acylcarnitine Profiling in Plasma Samples

  • 0Department of Surgery-Practical Skills, Iuliu Hațieganu University of Medicine and Pharmacy Cluj-Napoca, 400012 Cluj-Napoca, Romania.

|

|

Summary

This summary is machine-generated.

Plasma amino acid and acylcarnitine profiling reveals metabolic alterations in gastric cancer (GC). Specific metabolite changes correlate with tumour characteristics and recurrence risk, offering insights into GC biology.

Area Of Science

  • Biochemistry
  • Oncology
  • Metabolomics

Background

  • Gastric cancer (GC) is a leading malignancy with poor prognosis, often diagnosed late.
  • Metabolic reprogramming is crucial for GC development and progression.
  • Early diagnostic markers for GC remain limited.

Purpose Of The Study

  • To investigate plasma amino acid and acylcarnitine profiles in gastric cancer patients.
  • To correlate metabolic profiles with clinical parameters, tumor histology, and recurrence.
  • To understand the role of metabolic reprogramming in gastric cancer biology.

Main Methods

  • Flow-injection tandem mass spectrometry was employed for plasma metabolite analysis.
  • 62 gastric cancer patients and 70 healthy controls were included.
  • Metabolite levels were correlated with clinical and histological data.

Main Results

  • Gastric cancer patients exhibited reduced levels of key amino acids (Trp, Arg, Tyr, Met) and aromatic AAs.
  • Elevated unsaturated, hydroxylated, and dicarboxylic acylcarnitines indicated mitochondrial/peroxisomal dysfunction.
  • Metabolic heterogeneity was observed across subtypes, with the indeterminate subtype showing significant fatty acid oxidation disruption.
  • Decreased C6DC-carnitine and Cit synthesis correlated with higher recurrence risk.

Conclusions

  • Plasma profiling of amino acids and acylcarnitines provides valuable insights into gastric cancer biology.
  • Distinct metabolic adaptations reflect tumor biology, histological subtype, and treatment response.
  • Specific metabolites may serve as potential biomarkers for GC recurrence.